Radiotherapy for nasopharyngeal cancer.

{"article_title":"Radiotherapy for nasopharyngeal cancer.","author":"Blanchard P, Biau J, Huguet F, Racadot S, Berthold C, Wong-Hee-Kam S, Biston MC, Maingon P","journal_title":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","issn":"1769-6658","isbn":"","publication_date":"2022-02-01","volume":"26","issue":"1-Feb","first_page":"168","page_count":"","accession_number":"34953699","doi":"10.1016\/j.canrad.2021.08.009","publisher":"Elsevier","doctype":"Journal Article","subjects":"France; Nasopharyngeal Neoplasms radiotherapy; Antineoplastic Combined Chemotherapy Protocols therapeutic use; France; Humans; Nasopharyngeal Neoplasms diagnostic imaging; Nasopharyngeal Neoplasms drug therapy; Organs at Risk diagnostic imaging; Radiation Oncology; Rare Diseases radiotherapy; Societies, Medical","interest_area":["ENT"," Oncology"],"abstract":"Nasopharyngeal cancers are a rarity in France. Radiotherapy is the cornerstone of treatment, frequently combined with chemotherapy. The technical modality of radiotherapy is complex in this disease, which is located in the vicinity of numerous organs at risk. In this article, we will present the updated guidelines of the French society for radiation oncology (Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique, SFRO) on the indications, and technical details of radiotherapy in nasopharyngeal cancers. Copyright \u00a9 2021 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=34953699","isPdfLink":false,"isSAML":false,"an":"34953699","number_other":"","type_pub":"","issn_electronic":"1769-6658","languages":"English","language":"eng","date_entry":"Date Created: 20211226 Date Completed: 20220217 Latest Revision: 20220217","date_update":"20240104","titleSource":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique [Cancer Radiother] 2022 Feb-Apr; Vol. 26 (1-2), pp. 168-173. Date of Electronic Publication: 2021 Dec 22.","date_pub_cy":"","type_document":"","contract_publisher":"","authored_on":"2022-02-01","description":"Nasopharyngeal cancers are a rarity in France. Radiotherapy is the cornerstone of treatment, frequently combined with chemotherapy. The technical modality of radiotherapy is complex in this disease, which is located in the vicinity of numerous organs at risk. In this article, we will present the updated guidelines of the French society for radiation oncology (Société française de radiothérapie oncologique, SFRO) on the indications, and technical details of radiotherapy in nasopharyngeal cancers.<br \/> (Copyright © 2021 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.)","upload_link":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&scope=site&db=mdl&AN=34953699&authtype=shib&custid=ns346513&group=main&profile=eds","no_of_pages":"","authored_by":"Blanchard P, Biau J, Huguet F, Racadot S, Berthold C, Wong-Hee-Kam S, Biston MC, Maingon P"}